Insider Selling: CRISPR THERAPTC (CRSP) CEO Sells 5,303 Shares of Stock

CRISPR THERAPTC (NASDAQ:CRSP) CEO Rodger Novak sold 5,303 shares of CRISPR THERAPTC stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $15.02, for a total value of $79,651.06. Following the sale, the chief executive officer now directly owns 1,219,208 shares of the company’s stock, valued at $18,312,504.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Rodger Novak also recently made the following trade(s):

  • On Tuesday, May 30th, Rodger Novak sold 3,650 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $15.02, for a total value of $54,823.00.
  • On Wednesday, May 17th, Rodger Novak sold 50,000 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.26, for a total value of $813,000.00.
  • On Friday, May 5th, Rodger Novak sold 616 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.92, for a total value of $10,422.72.
  • On Thursday, May 4th, Rodger Novak sold 49,384 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.30, for a total value of $804,959.20.
  • On Thursday, April 20th, Rodger Novak sold 50,000 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $17.88, for a total value of $894,000.00.

Shares of CRISPR THERAPTC (NASDAQ CRSP) traded down 0.14% during mid-day trading on Monday, reaching $14.79. The company had a trading volume of 212,492 shares. CRISPR THERAPTC has a 52-week low of $11.63 and a 52-week high of $25.00. The stock’s market capitalization is $591.56 million. The company’s 50-day moving average is $15.56 and its 200 day moving average is $18.61.

CRISPR THERAPTC (NASDAQ:CRSP) last issued its earnings results on Thursday, May 11th. The company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.70 million during the quarter. Analysts anticipate that CRISPR THERAPTC will post ($2.41) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for CRISPR THERAPTC (NASDAQ:CRSP)

TRADEMARK VIOLATION WARNING: This piece was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/rodger-novak-sells-5303-shares-of-crispr-theraptc-crsp-stock-updated/985390.html.

Separately, Chardan Capital initiated coverage on CRISPR THERAPTC in a research note on Monday, March 27th. They set a “buy” rating and a $23.50 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $23.10.

A number of large investors have recently modified their holdings of CRSP. IHT Wealth Management LLC bought a new stake in shares of CRISPR THERAPTC during the first quarter valued at about $110,000. Morgan Stanley increased its stake in shares of CRISPR THERAPTC by 437.9% in the first quarter. Morgan Stanley now owns 20,526 shares of the company’s stock valued at $447,000 after buying an additional 16,710 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of CRISPR THERAPTC by 15.0% in the first quarter. Geode Capital Management LLC now owns 21,110 shares of the company’s stock valued at $459,000 after buying an additional 2,760 shares in the last quarter. Monashee Investment Management LLC increased its stake in shares of CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares in the last quarter. Finally, Paulson & CO. Inc. acquired a new position in CRISPR THERAPTC during the first quarter worth $1,099,000. 24.08% of the stock is owned by hedge funds and other institutional investors.

About CRISPR THERAPTC

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Decline Means Justin Verlander Could be on the Block
Tigers Decline Means Justin Verlander Could be on the Block
Miami Marlins Trade Adeiny Hechavarria to Tampa Bay
Miami Marlins Trade Adeiny Hechavarria to Tampa Bay
Baltimore Orioles Pitching Staff Continue to Fail
Baltimore Orioles Pitching Staff Continue to Fail
Cody Bellinger Continues Strong June at the Plate
Cody Bellinger Continues Strong June at the Plate
Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third


Leave a Reply

 
© 2006-2017 BBNS.